What’s Yet To Come From Insulin Pipeline
The insulin market is undergoing great change, with pricing pressures by payers in the US and a biosimilar long-acting insulin approved in Europe and headed for the US. Leading sponsors have prepared by developing new products that offer incremental improvements.
You may also be interested in...
Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.